Kyle J. Seamon
Revolution Medicines (United States)
ORCID: 0009-0005-5028-3752Pilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.
Indexed papers
Why this DataRank?
An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.
Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.
Read the full methodology →Papers
Driven by 5 papers. Top paper: “Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy”.
Bianca J. Lee, Jingjing Jiang, Aidan C.A. Tomlinson, Kyle J. Seamon, Alessia Mira +48 more
Kyle J. Seamon, Yulei Zhao, Yu Chi Yang, Jim Cregg, Dong-Sung Kim +31 more
Kyle J. Seamon, Edwin A. Saada, Joshua D. Podlevsky, Steven S. Branda, Jerilyn A. Timlin +2 more
Anthony S. Gizzi, Junru Cui, Matthew Egleston, Kyle J. Seamon, Michael DePasquale +4 more
Nicole Nasholm, Chiara Ambrogio, Anthony N. Milin, Yang Liu, Elsa Quintana +48 more